Personalized cell therapy takes on Lung-Lining tumors
NCT ID NCT07192900
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new immunotherapy called Fast TILs for people with metastatic cancer or mesothelioma that has spread to the pleura (the lining around the lungs). The treatment uses the patient's own immune cells collected from their pleural fluid, which are multiplied in a lab and then delivered back into the chest through a catheter, along with a low dose of Interleukin-2. The main goals are to see if this approach is safe and if the personalized cell product can be made reliably. Only 10 participants will be enrolled, and the active treatment lasts about three weeks, with follow-up over five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fast TILs (immune cells from the patient's own pleural fluid) plus Interleukin-2
What this could lead to
If it works, this could point toward a new treatment option for people with cancer that has spread to the lining of the lungs.
What could go wrong
This is a very early, first-in-human trial with only 10 participants. The treatment may not work, and there are unknown risks, including serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL EFFUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AHN West Penn Hospital
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact